Multimodality imaging of breast cancer experimental lung metastasis with bioluminescence and a monoclonal antibody dual-labeled with 89Zr and IRDye 800CW

Molecular Pharmaceutics

Volumn 9, Issue 8, 2012, Pages 2339-2349

  Hong, Hao ^a   Zhang, Yin ^b   Severin, Gregory W ^b   Yang, Yunan ^a   Engle, Jonathan W ^b   Niu, Gang ^c   Nickles, Robert J ^b   Chen, Xiaoyuan ^c   Leigh, Bryan R ^d   Barnhart, Todd E ^c   Cai, Weibo ^a,b,e  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^d TRACON Pharmaceuticals Inc   (United States)

^e UNIVERSITY OF WISCONSIN   (United States)

Author keywords

89Zr; breast cancer; CD105 (endoglin); lung metastasis; near infrared fluorescence (NIRF); positron emission tomography (PET); tumor angiogenesis

Indexed keywords

CETUXIMAB; DEFEROXAMINE; DEFEROXAMINE CETUXIMAB IRDYE 800CW ZR 89; DEFEROXAMINE MONOCLONAL ANTIBODY TRC 105 IRDYE 800CW ZR 89; ENDOGLIN; MONOCLONAL ANTIBODY; TRACER; TRC 105; UNCLASSIFIED DRUG; ZIRCONIUM; ZIRCONIUM 89;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BREAST CANCER; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SYNTHESIS; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; LUNG METASTASIS; MOUSE; NEAR INFRARED FLUORESCENCE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; TUMOR VOLUME;

ANIMALS; BENZENESULFONATES; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INDOLES; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; ZIRCONIUM;

EID: 84864706767     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300277f     Document Type: Article

References (53)

1. Mehlen, P.; Puisieux, A. Metastasis: a question of life or death Nat. Rev. Cancer 2006, 6, 449-58
2. Siegel, R.; Ward, E.; Brawley, O.; Jemal, A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths CA Cancer J. Clin. 2011, 61, 212-36
3. Weigelt, B.; Peterse, J. L.; van't Veer, L. J. Breast cancer metastasis: markers and models Nat. Rev. Cancer 2005, 5, 591-602 (Pubitemid 41081385)
4. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation Cell 2011, 144, 646-74
5. von Elstermann, M. Metastasis: Which way to the lungs? Nat. Rev. Cancer 2008, 8, 410-411
6. Ikushima, H.; Miyazono, K. TGFbeta signalling: a complex web in cancer progression Nat. Rev. Cancer 2010, 10, 415-24
7. Fonsatti, E.; Nicolay, H. J.; Altomonte, M.; Covre, A.; Maio, M. Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours Cardiovasc. Res. 2010, 86, 12-9
8. Seon, B. K.; Haba, A.; Matsuno, F.; Takahashi, N.; Tsujie, M.; She, X.; Harada, N.; Uneda, S.; Tsujie, T.; Toi, H.; Tsai, H.; Haruta, Y. Endoglin-targeted cancer therapy Curr. Drug Delivery 2011, 8, 135-43
9. Zhang, Y.; Yang, Y.; Hong, H.; Cai, W. Multimodality molecular imaging of CD105 (Endoglin) expression Int. J. Clin. Exp. Med. 2011, 4, 32-42
10. Dallas, N. A.; Samuel, S.; Xia, L.; Fan, F.; Gray, M. J.; Lim, S. J.; Ellis, L. M. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy Clin. Cancer Res. 2008, 14, 1931-7 (Pubitemid 351551101)
11. Mendelson, D. S.; Gordon, M. S.; Rosen, L. S.; Hurwitz, H.; Wong, M. K.; Adams, B. J.; Alvarez, D.; Seon, B. K.; Theuer, C. P.; Leigh, B. R. Phase I study of TRC105 (anti-CD105 [endoglin] antibody) therapy in patients with advanced refractory cancer J. Clin. Oncol. 2010, 28, 15s
12. Gambhir, S. S.; Czernin, J.; Schwimmer, J.; Silverman, D. H.; Coleman, R. E.; Phelps, M. E. A tabulated summary of the FDG PET literature J. Nucl. Med. 2001, 42, 1S-93S (Pubitemid 32423895)
13. 18F-based radiotracers Am. J. Nucl. Med. Mol. Imaging 2012, 2, 55-76
14. 18F-FDG PET in sarcoma treatment response imaging Am. J. Nucl. Med. Mol. Imaging 2011, 1, 47-53
15. 11C-acetate Am. J. Nucl. Med. Mol. Imaging 2012, 2, 33-47
16. 18F-FDG PET/CT: timing for evaluation of response to therapy remains a clinical challenge Am. J. Nucl. Med. Mol. Imaging 2011, 1, 63-64
17. Koo, V.; Hamilton, P. W.; Williamson, K. Non-invasive in vivo imaging in small animal research Cell Oncol. 2006, 28, 127-39 (Pubitemid 44427396)
18. Pomper, M. G.; Lee, J. S. Small animal imaging in drug development Curr. Pharm. Des. 2005, 11, 3247-72 (Pubitemid 41300775)
19. Wu, A. M. Antibodies and antimatter: the resurgence of immuno-PET J. Nucl. Med. 2009, 50, 2-5
20. van Dongen, G. A.; Vosjan, M. J. Immuno-positron emission tomography: shedding light on clinical antibody therapy Cancer Biother. Radiopharm. 2010, 25, 375-85
21. Zhang, Y.; Hong, H.; Cai, W. PET tracers based on Zirconium-89 Curr. Radiopharm. 2011, 4, 131-139
22. van Dam, G. M.; Themelis, G.; Crane, L. M.; Harlaar, N. J.; Pleijhuis, R. G.; Kelder, W.; Sarantopoulos, A.; de Jong, J. S.; Arts, H. J.; van der Zee, A. G.; Bart, J.; Low, P. S.; Ntziachristos, V. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results Nat. Med. 2011, 17, 1315-9
23. Chin, P. T. K.; Beekman, C. A. C.; Buckle, T.; Josephson, L.; van Leeuwen, F. W. B. Multispectral visualization of surgical safety-margins using fluorescent marker seeds Am. J. Nucl. Med. Mol. Imaging 2012, 2, 151-162
24. Zhang, Y.; Hong, H.; Engle, J. W.; Yang, Y.; Barnhart, T. E.; Cai, W. Positron emission tomography and near-infrared fluorescence imaging of vascular endothelial growth factor with dual-labeled bevacizumab Am. J. Nucl. Med. Mol. Imaging 2012, 2, 1-13
25. Cai, W.; Hsu, A. R.; Li, Z. B.; Chen, X. Are quantum dots ready for in vivo imaging in human subjects? Nanoscale Res. Lett. 2007, 2, 265-81 (Pubitemid 47139333)
26. Cai, W.; Hong, H. In a "nutshell": intrinsically radio-labeled quantum dots Am. J. Nucl. Med. Mol. Imaging 2012, 2, 136-140
27. Huang, X.; Lee, S.; Chen, X. Design of "smart" probes for optical imaging of apoptosis Am. J. Nucl. Med. Mol. Imaging 2011, 1, 3-17
28. Cai, W.; Chen, K.; Li, Z. B.; Gambhir, S. S.; Chen, X. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature J. Nucl. Med. 2007, 48, 1862-1870 (Pubitemid 350099333)
29. Sampath, L.; Kwon, S.; Hall, M. A.; Price, R. E.; Sevick-Muraca, E. M. Detection of Cancer Metastases with a Dual-labeled Near-Infrared/Positron Emission Tomography Imaging Agent Trans. Oncol. 2010, 3, 307-217
30. Zhang, Y.; Hong, H.; Engle, J. W.; Yang, Y.; Theuer, C. P.; Barnhart, T. E.; Cai, W. Positron Emission Tomography and Optical Imaging of Tumor CD105 Expression with a Dual-Labeled Monoclonal Antibody Mol. Pharmaceutics 2012, 9, 645-53
31. Cai, W.; Niu, G.; Chen, X. Multimodality imaging of the HER-kinase axis in cancer Eur. J. Nucl. Med. Mol. Imaging 2008, 35, 186-208 (Pubitemid 350234146)
32. Cao, Q.; Cai, W.; Niu, G.; He, L.; Chen, X. Multimodality imaging of IL-18-binding protein-Fc therapy of experimental lung metastasis Clin. Cancer Res. 2008, 14, 6137-45
33. Holland, J. P.; Sheh, Y.; Lewis, J. S. Standardized methods for the production of high specific-activity zirconium-89 Nucl. Med. Biol. 2009, 36, 729-39
34. 89Zr-Df-TRC105 Eur. J. Nucl. Med. Mol. Imaging 2012, 39, 138-148
35. Vosjan, M. J.; Perk, L. R.; Visser, G. W.; Budde, M.; Jurek, P.; Kiefer, G. E.; van Dongen, G. A. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine Nat. Protoc. 2010, 5, 739-43
36. Yang, Y.; Zhang, Y.; Hong, H.; Liu, G.; Leigh, B. R.; Cai, W. In vivo near-infrared fluorescence imaging of CD105 expression Eur. J. Nucl. Med. Mol. Imaging 2011, 38, 2066-76
37. 3 Cancer Res. 2006, 66, 9673-81 (Pubitemid 44623667)
38. Cai, W.; Chen, K.; Mohamedali, K. A.; Cao, Q.; Gambhir, S. S.; Rosenblum, M. G.; Chen, X. PET of vascular endothelial growth factor receptor expression J. Nucl. Med. 2006, 47, 2048-2056 (Pubitemid 47544993)
39. Sgouros, G. Dosimetry of internal emitters J. Nucl. Med. 2005, 46 (Suppl. 1) 18S-27S (Pubitemid 47619015)
40. Takahashi, N.; Haba, A.; Matsuno, F.; Seon, B. K. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide Cancer Res. 2001, 61, 7846-54 (Pubitemid 33049374)
41. Fonsatti, E.; Jekunen, A. P.; Kairemo, K. J.; Coral, S.; Snellman, M.; Nicotra, M. R.; Natali, P. G.; Altomonte, M.; Maio, M. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model Clin. Cancer Res. 2000, 6, 2037-43 (Pubitemid 30305103)
42. 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer Clin. Pharmacol. Ther. 2010, 87, 586-92
43. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo J. Nucl. Med. 2010, 51, 1293-300
44. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922 J. Nucl. Med. 2010, 51, 761-7
45. Cutler, P. D.; Schwarz, S. W.; Anderson, C. J.; Connett, J. M.; Welch, M. J.; Philpott, G. W.; Siegel, B. A. Dosimetry of copper-64-labeled monoclonal antibody 1A3 as determined by PET imaging of the torso J. Nucl. Med. 1995, 36, 2363-71
46. Cai, W.; Ebrahimnejad, A.; Chen, K.; Cao, Q.; Li, Z. B.; Tice, D. A.; Chen, X. Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice Eur. J. Nucl. Med. Mol. Imaging 2007, 34, 2024-36 (Pubitemid 350212123)
47. Frese, K. K.; Tuveson, D. A. Maximizing mouse cancer models Nat. Rev. Cancer 2007, 7, 645-58 (Pubitemid 47327410)
48. Hong, H.; Yang, Y.; Zhang, Y.; Engle, J. W.; Barnhart, T. E.; Nickles, R. J.; Leigh, B. R.; Cai, W. Positron emission tomography imaging of CD105 expression during tumor angiogenesis Eur. J. Nucl. Med. Mol. Imaging 2011, 38, 1335-43
49. Heskamp, S.; van Laarhoven, H. W.; Molkenboer-Kuenen, J. D.; Franssen, G. M.; Versleijen-Jonkers, Y. M.; Oyen, W. J.; van der Graaf, W. T.; Boerman, O. C. ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model J. Nucl. Med. 2010, 51, 1565-72
50. Matsuno, F.; Haruta, Y.; Kondo, M.; Tsai, H.; Barcos, M.; Seon, B. K. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies Clin. Cancer Res. 1999, 5, 371-82 (Pubitemid 29085191)
51. Meijs, W. E.; Herscheid, J. D. M.; Haisma, H. J.; Pinedo, H. M. Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89 Int. J. Radiat. Appl. Instrum., A, Appl. Radiat. Isot. 1992, 43, 1443-1447
52. Perk, L. R.; Vosjan, M. J.; Visser, G. W.; Budde, M.; Jurek, P.; Kiefer, G. E.; van Dongen, G. A. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging Eur. J. Nucl. Med. Mol. Imaging 2010, 37, 250-9
53. Borjesson, P. K.; Jauw, Y. W.; Boellaard, R.; de Bree, R.; Comans, E. F.; Roos, J. C.; Castelijns, J. A.; Vosjan, M. J.; Kummer, J. A.; Leemans, C. R.; Lammertsma, A. A.; van Dongen, G. A. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients Clin. Cancer Res. 2006, 12, 2133-40